406 results on '"Avvisati G"'
Search Results
2. PD-1 /PD-L1 checkpoint in hematological malignancies
3. PML–RARα kinetics and impact of FLT3–ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy
4. Supplement to: Retinoic acid and arsenic trioxide for acute promyelocytic leukemia.
5. High incidence of post-transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib-based regimens: a survey from the Rome Transplant Network
6. VERY LONG-TERM RESULTS OF ALL-TRANS RETINOIC ACID AND ARSENIC TRIOXIDE IN NON-HIGH RISK ACUTE PROMYELOCYTIC LEUKEMIA: LATEST UPDATE OF THE ITALIAN-GERMAN APL0406 RANDOMIZED TRIAL
7. Occurrence of thrombotic events in acute promyelocytic leukemia correlates with consistent immunophenotypic and molecular features
8. Insight into the electronic structure of semiconducting $ensuremath{epsilon} ext{ensuremath{-}}mathrm{GaSe}$ and $ensuremath{epsilon} ext{ensuremath{-}}mathrm{InSe}$
9. Erythropoietin in Patients Undergoing Elective Joint Arthroplasty and Preoperative Autologous Blood Donation
10. Treatment of elderly patients (≥60 years) with newly diagnosed acute promyelocytic leukemia. Results of the Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols
11. Fibrin glue for treatment of severe haemorrhagic cystitis following allogeneic haematopoietic stem cell transplantation: 256
12. Transfusion Strategy to Reduce Allogeneic Transfusion in Major Orthopaedic Surgery: P41
13. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol
14. Prevention of delayed emesis induced by moderately emetogenic chemotherapy in patients with acute emesis: A pilot study with ACTH-depot plus tropisetron
15. The Potential Application of the Allogeneic Transplant by the Policy of Widespread Donor Search: an Intention- To-Treat Analysis from the Rome Transplant Network: P1122
16. Rome Transplant Network, a metropolitan haematopoietic stem cell transplant programme: P824
17. The central role regarding HPC transport of the unique processing facility in a multi-centre programme following JACIE standards: P831
18. Acute promyelocytic leukemia: a curable disease
19. A case of primary MALT lymphoma of the endometrium presenting as an asymptomatic polyp
20. Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling: 1 Week On/1 Week Off
21. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971–1991)
22. All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase
23. Fibrin glue for endoscopic gastrointestinal bleeding in patients with impaired haemostasis
24. BAVC regimen and autologous bone marrow transplantation for APL patients in second molecular remission: updated results
25. MANAGEMENT of INFLAMMATORY PANCREATIC MASSES MIMICKING PANCREATIC CARCINOMA: OUR EXPERIENCE: 29
26. Intraventricular thrombosis during all-trans retinoic acid treatment in acute promyelocytic leukemia
27. Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients
28. Melphalan treatment in patients with myelofibrosis with myeloid metaplasia
29. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study
30. AIDA PROTOCOL: THE ITALIAN WAY OF TREATING APL
31. THERAPY OF MINIMAL DISEASE RECURRENCE IN ACUTE PROMYELOCYTIC LEUKEMIA
32. CLINICAL AND BIOLOGICAL RELEVANCE OF IMMUNOPHENOTYPE IN ACUTE PROMYELOCYTIC LEUKEMIA: A STUDY OF 196 CASES
33. Treatment of high-risk myelodysplastic syndromes with lymphoblastoid alpha interferon
34. Phase behaviour of colloidal molecules with anisotropic interactions
35. Coranaric thrombotic events in acute promyelocytic leukemia during all-trans retinoic acid treatment: a role for adhesion molecules over expression?
36. ROLE OF TREATMENT ON THE DEVELOPMENT OF SECONDARY MALIGNANCIES IN PATIENTS WITH ESSENTIAL THROMBOCYTEMIA
37. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy following autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma
38. RANDOMIZED PHASE II TRIAL ON PRIMARY CHEMOTHERAPY WITH HIGH-DOSE METHOTREXATE (HD-MTX) ALONE OR ASSOCIATED WITH HIGH-DOSE CYTARABINE (HD-ARAC) FOR PATIENTS WITH PRIMARY CNS LYMPHOMA (IELSG # 20 TRIAL): TOLERABILITY, ACTIVITY AND SURVIVAL ANALYSES
39. EP-1252: Dosimetric and clinical outcomes of radiotherapy for early-stage lymphoma mediastinal involvement
40. Pathogenetic, Clinical, and Prognostic Features of Adult t(4;11)(q21;q23)/MLL-AF4 Positive B-Cell Acute Lymphoblastic Leukemia
41. GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors
42. AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance
43. The Potential Application of the Allogeneic Transplant by the Policy of Widespread Donor Search: an Intention- To-Treat Analysis from the Rome Transplant Network
44. Thrombophilic screening in young patients (
45. A RETROSPECTIVE ANALYSIS ON 285 PATIENTS WITH IDIOPATIC MYELOFIBROSIS FOLLOWED IN THE LAZIO REGION DURING 20 YEARS: IMPACT OF PROGNOSTIC FACTORS ON SURVIVAL AND PROGRESSION TO AML
46. The potential application of the allogeneic transplant according to a widespread donor search policy: an intention-to-treat analysis from the Rome Transplant Network
47. Thrombophilic screening in patients with paroxysmal nocturnal haemoglobinuria: a pilot study
48. Antiphospholipid Antibodies and Thrombotic Complications In Patients With Paroxysmal Nocturnal Hemoglobinuria
49. Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group
50. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.